JAZZ · Categories · M&A
JAZZ - Mergers and acquisitions
Jazz Pharmaceuticals plc (JAZZ) mergers and acquisitions - real-time wire coverage filtered to M&A only.
Recent M&A for JAZZ
- Jazz Pharmaceuticals Completes Acquisition of Actio BiosciencesAcquisition adds ABS-1230, a clinical-stage, potential first-in-class precision therapy for KCNT1-related epilepsyTransaction strengthens Jazz's epilepsy pipeline and reinforces its commitment to advance treatment options in rare diseaseDUBLIN, Sept. 15, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) ("Jazz" or the "Company") today announced the successful completion of its acquisition of privately-held Actio Biosciences, Inc. ("Actio") for $820 million upfront. Actio is now a wholly-owned subsidiary of Jazz."ABS-1230 holds the promise of being a transformative, first-in-class therapy for individuals living with KCNT1-related epilepsy," said Renee Gala, president and chief execu
- Jazz Pharmaceuticals Completes Acquisition of Chimerix- Addition of dordaviprone strengthens Jazz's late-stage oncology pipeline and reinforces commitment to addressing rare diseases with significant unmet need - DUBLIN, April 21, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) ("Jazz" or the "Company") today announced the successful completion of its acquisition of Chimerix, Inc. ("Chimerix") for approximately $935 million in cash. Chimerix is now a wholly owned subsidiary of Jazz. "Bringing Chimerix into Jazz adds a novel medicine to our oncology portfolio and advances our efforts to address unmet patient needs," said Bruce Cozadd, chairman and chief executive officer of Jazz. "Dordaviprone has the potential to become the first an
- Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 2 Clinical Trial Evaluating JZP150 for Once-Daily Treatment of Adults with Post-Traumatic Stress DisorderDUBLIN, Dec. 30, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced that the first patient has been enrolled in a Phase 2 clinical trial evaluating the safety and efficacy of JZP150, an investigational first-in-class small molecule for the treatment of adults with post-traumatic stress disorder (PTSD). JZP150 is a highly selective inhibitor of the enzyme fatty acid amide hydrolase (FAAH), designed to address the underlying cause of PTSD (impairment of fear extinction and its consolidation), as well as patients' associated symptoms (anxiety, insomnia and nightmares). JZP150 was granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for PTSD bas